Table 4 Improved assessment of thrombo-ischemic and major bleeding events in patients with CAD integrating platelet lipid species.

From: Machine learning insights into thrombo-ischemic risks and bleeding events through platelet lysophospholipids and acylcarnitine species

Variables

Ischemic Endpoint (n = 25)

Bleeding Endpoint (n = 16)

HR (95% CI)

p-Value

HR (95% CI)

p-Value

LVEF

0.37 (0.12–1.12)

0.079

2.25 (0.36–14.3)

0.378

HbA1c

5.69 (0.3–107.89)

0.247

0.03 (0.01–15.81)

0.261

Platelet aggregation

2.1 (0.21–21.17)

0.530

4.-6 (0.28–87.6)

0.274

LDL

4.67 (0.67–32.63)

0.120

0.78 (0.05–12.95)

0.865

HDL

4.47 (0.21–94.1)

0.335

0.16 (0.01–21.85)

0.462

Triglycerides

0.43 (0.01–65.25)

0.743

0.01 (9.3e−10–19.98)

0.143

LPE

0.3 (0.01–4.3)

0.377

3.07 (0.33–29.58)

0.332

CAR

21.89 (1.38–346.4)

0.029

162.35 (6.91–3816.13)

0.002

LPE/CAR Ratio

90.83 (2.2–3745.32)

0.018

5.93 (0.13–265.18)

0.359

  1. Cox proportional hazard model including platelet lipid signatures. Variables significantly (p < 0.05) contributing to the prediction of adverse events during the three-year follow-up are highlighted. HR, hazard ratio; CI, confidence interval; LVEF, left ventricular ejection fraction; LDL, low-density lipoprotein; HDL, high-density lipoprotein; LPE, lysophosphatidylethanolamines; CAR, acylcarnitines.
Back to article page